secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001104659-23-113591
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics reports Q3 net loss of $6.7M; updates on Alzheimer’s and DLB trials
--------------------------------------------------------------------------------

- Net loss of $6.7M ($0.22 per share) in Q3 2023 vs $6.6M ($0.29 per share) in Q3 2022.
- Cash and equivalents $33.0M; total grant funds $74.3M from NIA; cash runway through Nov 2024.
- Phase 2 SHINE Alzheimer’s topline results expected mid-2024; SHIMMER DLB data also mid-2024.
- START trial initiated allowing lecanemab combo therapy; MAGNIFY dry AMD study dosing started.
- R&D expenses $11.7M (up 41% YoY); G&A $3.1M (down 30% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923113591/0001104659-23-113591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923113591/tm2329528d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-113591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer